Proactive Investors - Run By Investors For Investors

Cosmos Holdings appoints top portfolio manager to advisory board

Tom Kolefas joins the international pharmaceutical company after managing both mutual fund and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York
board room
The appointment of Kolefas follows the recent addition of Anastasios Tzikas, former CEO of Singular Northern Greece SA, one of Greece’s largest software vendors, to the Cosmos board

Cosmos Holdings Inc (OTCQB:COSM) announced Friday that portfolio manager Tom Kolefas has been tapped to serve on its advisory board.

Kolefas joins the international pharmaceutical company after more than 25 years spent on Wall Street’s buyside where he managed both mutual funds and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York.

READ: Cosmos Holdings acquires Cosmofarm in Greece

Kolefas also boasts considerable industry experience as a chemical engineer and corporate development officer at Engelhard/BASF.

“Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, CEO of Cosmos in a statement. “He has a track record for success in identifying value within the mid-cap space. We look forward to his contribution as we position ourselves for continued growth.”

For his part, Kolefas is eager to come on board at Cosmos and advance its business efforts.

READ: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

“Cosmos has a well-thought out, balanced strategy of organic growth, market share gains, new product introductions and acquisitions to capitalize on the growth in the drug, nutraceutical, vitamin and Europe-only cannabis end-markets in Europe, the U.S. and ultimately, the rest of the world," Kolefas said in a statement.

Cosmos Holdings Inc. is an international pharmaceutical company that specializes in acquiring, developing, and commercializing medicines. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and in the UK.

Cosmos shares closed up 8.3% to hit $3.00 on Thursday.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Related Articles

patch
Wed
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use